EU Proposes Recall Of Clopidogrel Because Of GMP Failures At Indian Glochem
This article was originally published in PharmAsia News
Executive SummarySwiss company Acino Pharma says it is unnecessary to recall its generic clopidogrel products from the EU market, even though its Indian API supplier, Glochem Industries, failed a good manufacturing practices inspection
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.